A search on oncoKB for the actionability of PIK3CA, AKT1, ESR1, and ERBB2/HER2 oncogenic mutations on BC identified 7 protocols, 3 of which are FDA-approved (Alpelisib, Neratinib and Abemaciclib. This evidence concerns the gene ESR1 and breast cancer.